ICES13 - Market and Trends

Innovacell addresses the large market for incontinence treatments, worth more than 10 billion EUR, a figure growing at roughly 10 per cent per year. Today an estimated total of 23 million SUI patients have received treatment in the seven key markets: US, Germany, Japan, UK, France, Italy and Spain. Every year an additional 800,000 SUI patients are receiving treatment in these countries.

The market for SUI treatments includes various types of pharmaceutical and surgical therapies, medical devices and consumables. Over the past ten years, more than 1 million SUI patients worldwide have opted for the surgical implantation of a suburethral sling.

Innovacell’s lead product ICES13 addresses a large market with approximately seven million patients in the top seven global pharmaceutical markets. More than one million people would benefit directly from Innovacell’s ICES13 therapy in Western Europe alone.